David Lawson Morris Selected Research

Bromelains (Bromelain)

1/2020	Enhancing the potency of chemotherapeutic agents by combination with bromelain and N-acetylcysteine - an in vitro study with pancreatic and hepatic cancer cells.
1/2016	Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.
11/2014	Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy.
5/2013	Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma.
1/2013	Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Lawson Morris Research Topics

Disease

15	Neoplasms (Cancer) 01/2018 - 12/2003
5	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 03/2006
4	Ascites 04/2013 - 03/2006
3	Pseudomyxoma Peritonei 01/2021 - 01/2014
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2016 - 11/2014
2	Peritoneal Neoplasms 01/2016 - 03/2006
2	Carcinoma (Carcinomatosis) 11/2014 - 01/2013
1	Liver Neoplasms (Liver Cancer) 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017
1	Carcinogenesis 01/2017
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2014
1	Breast Neoplasms (Breast Cancer) 05/2013
1	Mesothelioma 05/2013
1	Hypoxia (Hypoxemia) 04/2013
1	Colonic Neoplasms (Colon Cancer) 01/2013
1	Ovarian Epithelial Carcinoma 01/2012
1	Retinal Neovascularization 07/2010
1	Hyperoxia 07/2010
1	Colorectal Neoplasms (Colorectal Cancer) 03/2006
1	Burns 12/2003
1	Pneumothorax 09/2003
1	Neoplasm Metastasis (Metastasis) 09/2003
1	Shock 10/2002
1	Wounds and Injuries (Trauma) 10/2002
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 10/2002

Drug/Important Bio-Agent (IBA)

5	Bromelains (Bromelain)IBA 01/2020 - 01/2013
4	Albendazole (Albenza)FDA Link 01/2017 - 03/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2013 - 03/2006
3	Acetylcysteine (Siran)FDA LinkGeneric 01/2020 - 11/2014
3	MucinsIBA 01/2017 - 01/2014
3	Proteins (Proteins, Gene)FDA Link 01/2014 - 01/2012
2	Glycoproteins (Glycoprotein)IBA 01/2017 - 05/2013
2	Cisplatin (Platino)FDA LinkGeneric 01/2016 - 01/2013
2	lissamine rhodamine B (sulforhodamine B)IBA 11/2014 - 01/2013
2	Protein Isoforms (Isoforms)IBA 01/2014 - 01/2012
1	1-dodecylpyridoxal (PLD)IBA 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018
1	Gemcitabine FDA Link 01/2018
1	monepantelIBA 01/2018
1	liposomal doxorubicin (Doxil)FDA Link 01/2018
1	Biological ProductsIBA 01/2017
1	CyclodextrinsIBA 01/2017
1	Vincristine (Oncovin)FDA LinkGeneric 01/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2016
1	Fluorouracil (Carac)FDA LinkGeneric 01/2016
1	Expectorants (Mucolytics)IBA 01/2014
1	Estradiol (Delestrogen)FDA LinkGeneric 06/2013
1	Interleukin-6 (Interleukin 6)IBA 04/2013
1	Drinking WaterIBA 04/2013
1	Minocycline (Cyclops)FDA LinkGeneric 04/2013
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 04/2013
1	Phosphotransferases (Kinase)IBA 04/2013
1	CytokinesIBA 04/2013
1	CaspasesIBA 01/2013
1	Oncogene Proteins (Oncogene Protein)IBA 01/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2012
1	Retinaldehyde (Retinal)IBA 07/2010
1	Messenger RNA (mRNA)IBA 03/2006
1	Cimetidine (Biomet)FDA LinkGeneric 10/2002

Therapy/Procedure

5	Therapeutics 01/2018 - 11/2014
3	Drug Therapy (Chemotherapy) 01/2017 - 05/2014
3	Radiofrequency Ablation 07/2004 - 09/2003
2	Cytoreduction Surgical Procedures 01/2021 - 01/2016
1	Hyperthermic Intraperitoneal Chemotherapy 01/2021
1	Catheters 01/2014
1	Laparotomy 12/2003
1	Chest Tubes (Chest Tube) 09/2003
1	Electrodes (Electrode) 09/2003
1	Punctures 10/2002